A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

Antibody-directed enzyme prodrug therapy is a targeted therapy in which a prodrug is activated selectively at the tumour site by an enzyme, which has been targeted to the tumour by an antibody (antibody-enzyme conjugate). Previous clinical trials have shown evidence of tumour response, however, the...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Francis, R J, Sharma, S K, Springer, C, Green, A J, Hope-Stone, L D, Sena, L, Martin, J, Adamson, K L, Robbins, A, Gumbrell, L, O'Malley, D, Tsiompanou, E, Shahbakhti, H, Webley, S, Hochhauser, D, Hilson, A J, Blakey, D, Begent, R H J
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2002
Sujets:
Clinical
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2364249/
https://ncbi.nlm.nih.gov/pubmed/12237768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600517
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires